Xenetic Biosciences, Inc. (NASDAQ:XBIO – Get Free Report) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 37,018 shares, an increase of 237.7% from the October 15th total of 10,961 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average trading volume of 31,416 shares, the days-to-cover ratio is presently 1.2 days.
Xenetic Biosciences Stock Up 5.1%
Shares of NASDAQ:XBIO opened at $1.75 on Friday. Xenetic Biosciences has a fifty-two week low of $1.58 and a fifty-two week high of $4.94. The firm’s 50-day simple moving average is $2.48 and its 200-day simple moving average is $2.81. The company has a market cap of $4.00 million, a price-to-earnings ratio of -1.49 and a beta of 2.36.
Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.72) EPS for the quarter. The business had revenue of $0.73 million during the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Read Our Latest Research Report on XBIO
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for oncology indications. The company’s primary focus is its XCART platform, an autologous cell-therapy technology designed to modify a patient’s own T cells to recognize and attack cancer cells. Xenetic has applied the XCART platform to potential treatments for B-cell malignancies, including programs intended to target specific antigens found on cancerous B cells. The company’s research and development activities have centered on advancing personalized immunotherapies through preclinical and clinical development.
Featured Stories
- Five stocks we like better than Xenetic Biosciences
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
